Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

February 15, 2018February 15, 2018

NICE Opinion Limiting Esbriet to UK Patients with Moderate to Severe IPF Disappoints, patientMpower Says

The digital healthcare company patientMpower expressed disappointment at the opinion issued by an influential U.K. healthcare advisory group to limit the use of Esbriet (pirfenidone, marketed by Genentech) to patients with moderate to ... Read more

February 12, 2018February 12, 2018

Vanderbilt Team to Test Antiviral Therapy for Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis, News

A Vanderbilt University team will study whether adding a commonly used antiviral medicine to standard treatments for idiopathic pulmonary fibrosis can help stop or reverse the disease’s progress. IPF is a lung ... Read more

February 9, 2018February 9, 2018

Yale Study Reveals the Role a Previously Overlooked Cell Type Plays in IPF Progression

Idiopathic Pulmonary Fibrosis, News

A new study from Yale University has found that cells located along the walls of small blood vessels in the lung, called pericytes, promote the progression of idiopathic pulmonary fibrosis (IPF). The ... Read more

February 6, 2018February 6, 2018

Single Blood Test Screens for 8 Cancer Types, Helps Spot Tumor Location

Lung Cancer, News

A new blood test can screen for eight cancer types and help spot the tumor location, a recent study from Johns Hopkins Kimmel Cancer Center shows. The research, “Detection and localization ... Read more

January 26, 2018January 26, 2018

Three Winners Will Share $1 Million for Innovation in IPF Catalyst Challenge

Idiopathic Pulmonary Fibrosis, News

Three companies will equally share $1 million for winning the IPF Catalyst Challenge, a competition that fosters innovative solutions for helping idiopathic pulmonary fibrosis (IPF) patients. The winners are Advanced Interactive Response Systems ... Read more

January 23, 2018January 23, 2018

Interstitial Lung Disease Diagnoses Usually Inaccurate, Emotionally Trying, Patient Survey Shows

Idiopathic Pulmonary Fibrosis, News

A nationwide patient survey highlights the lengthy and often inaccurate diagnosis of interstitial lung disease (ILD), as well as the emotional stress it causes in patients. The research, “Barriers to ... Read more

January 19, 2018January 19, 2018

Eiger BioPharmaceuticals Discontinues Development of Ubenimex in PAH After Disappointing Results

News, Pulmonary Hypertension

Eiger BioPharmaceuticals will discontinue the development of ubenimex as a therapy for pulmonary arterial hypertension (PAH) due to disappointing results in the Phase 2 LIBERTY clinical trial. The treatment failed to ... Read more

January 11, 2018January 11, 2018

Bellerophon Enrolls First Patient in Study of INOpulse to Treat PH Linked to Interstitial Lung Disease

Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

A Phase 2b clinical study evaluating INOpulse as a treatment for pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) enrolled the first patient, Bellerophon Therapeutics has announced. Patients with ... Read more

January 10, 2018January 10, 2018

Insurance Coverage Affects Treatment Given Small-cell Lung Cancer Patients in US, Study Shows

Lung Cancer, News

Insurance status for people in the U.S. with non-metastatic small-cell lung cancer (SCLC) can determine both the type of treatment they are given and their likelihood of survival, a new study ... Read more

October 24, 2017October 24, 2017

Ofev Improves IPF Patients’ Lung Function Over the Long Term, Trial and Extension Show

Idiopathic Pulmonary Fibrosis, News

Long-term treatment with Boehringer Ingelheim‘s Ofev (nintedanib) improved the lung function and reduced the flare-ups of people with idiopathic pulmonary fibrosis, results of a Phase 2 clinical trial and its extension show. ... Read more